(VIANEWS) – BanColombia S.A. (CIB), New York Community Bancorp (NYCB), DexCom (DXCM) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. BanColombia S.A. (CIB)
56.6% sales growth and 16.94% return on equity
Bancolombia S. A. provides various banking products and services to individual and corporate customers in Colombia, Panama, Puerto Rico, El Salvador, Costa Rica, and Guatemala. The company operates through nine segments: Banking Colombia, Banking Panama, Banking El Salvador, Banking Guatemala, Trust, Investment Banking, Brokerage, International Banking, and All Other. It offers checking and savings accounts, fixed term deposits, and investment products; trade financing, loans funded by domestic development banks, working capital loans, credit cards, personal and vehicle loans, payroll loans, and overdrafts; financial support to real estate developers and mortgages for individuals and companies; and financial and operating leasing services. The company also provides hedging instruments, including futures, forwards, options, and swaps; and brokerage, investment advisory, and private banking services, including selling and distributing equities, futures, foreign currencies, fixed income securities, mutual funds, and structured products. In addition, it offers cash management services; foreign currency transaction services; life, auto, commercial, and homeowner's insurance products; and online and computer banking services. Further, the company provides investment banking services comprising project and acquisition finance, debt and equity capital markets, principal investments, M&A, restructurings, and structured financing; money market accounts, mutual and pension funds, private equity funds, payment trust, custody, and corporate trust; and digital banking platform, transportation, securities brokerage, maintenance and remodeling, advertising and marketing, and outsourcing services, as well as credit cards. As of December 31, 2020, it operated 1,057 branches; 18,631 banking correspondents; 535 PAMs; 215 kiosks in El Salvador and 137 in Colombia; and 6,124 automatic teller machines. Bancolombia S.A. was incorporated in 1945 and is headquartered in MedellÃn, Colombia.
Earnings Per Share
As for profitability, BanColombia S.A. has a trailing twelve months EPS of $6.69.
PE Ratio
BanColombia S.A. has a trailing twelve months price to earnings ratio of 5.09. Meaning, the purchaser of the share is investing $5.09 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.94%.
Volume
Today’s last reported volume for BanColombia S.A. is 425621 which is 85.37% above its average volume of 229595.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Dec 26, 2023, the estimated forward annual dividend rate is 2.86 and the estimated forward annual dividend yield is 8.41%.
Yearly Top and Bottom Value
BanColombia S.A.’s stock is valued at $34.05 at 00:22 EST, below its 52-week high of $34.43 and way above its 52-week low of $21.55.
Sales Growth
BanColombia S.A.’s sales growth is 71.8% for the present quarter and 56.6% for the next.
2. New York Community Bancorp (NYCB)
50.8% sales growth and 31.55% return on equity
New York Community Bancorp, Inc. operates as the bank holding company for Flagstar Bank, N.A. that provides banking products and services in the United States. The company's deposit products include interest-bearing checking and money market, savings, non-interest-bearing, and retirement accounts, as well as certificates of deposit. Its loan products comprise multi-family loans; commercial real estate loans; acquisition, development, and construction loans; commercial and industrial loans; one-to-four family loans; specialty finance loans and leases; warehouse loans; and other loans, such as home equity lines of credit, boat and recreational vehicle indirect lending, point of sale consumer loans, and other consumer loans, including overdraft loans. The company also offers cash management products; non-deposit investment and insurance products; and online banking, mobile banking, and bank-by-phone services. It primarily serves individuals, small and mid-size businesses, and professional associations. The company was formerly known as Queens County Bancorp, Inc. and changed its name to New York Community Bancorp, Inc. in November 2000. New York Community Bancorp, Inc. was founded in 1859 and is headquartered in Hicksville, New York.
Earnings Per Share
As for profitability, New York Community Bancorp has a trailing twelve months EPS of $3.91.
PE Ratio
New York Community Bancorp has a trailing twelve months price to earnings ratio of 2.71. Meaning, the purchaser of the share is investing $2.71 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.55%.
Yearly Top and Bottom Value
New York Community Bancorp’s stock is valued at $10.59 at 00:22 EST, way below its 52-week high of $14.22 and way higher than its 52-week low of $5.81.
Revenue Growth
Year-on-year quarterly revenue growth grew by 187.4%, now sitting on 2.77B for the twelve trailing months.
Moving Average
New York Community Bancorp’s value is above its 50-day moving average of $9.79 and below its 200-day moving average of $10.65.
3. DexCom (DXCM)
28.1% sales growth and 18.42% return on equity
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, DexCom has a trailing twelve months EPS of $0.92.
PE Ratio
DexCom has a trailing twelve months price to earnings ratio of 140.62. Meaning, the purchaser of the share is investing $140.62 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.42%.
Sales Growth
DexCom’s sales growth is 24.1% for the present quarter and 28.1% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
DexCom’s EBITDA is 122.4.
Previous days news about DexCom(DXCM)
- According to Zacks on Monday, 22 January, "This facility will likely help DexCom to support its supply of rtCGM sensors in Europe."
4. CNA Financial Corporation (CNA)
10.6% sales growth and 15.48% return on equity
CNA Financial Corporation provides commercial property and casualty insurance products primarily in the United States. It operates through Specialty, Commercial, International, Life & Group, and Corporate & Other segments. The company offers professional liability coverages and risk management services to various professional firms, including architects, real estate agents, and accounting and law firms; directors and officers, employment practices, fiduciary, and fidelity coverages to small and mid-size firms, public and privately held firms, and not-for-profit organizations; professional and general liability, as well as associated standard property and casualty coverages for healthcare industry; surety and fidelity bonds; and warranty and alternative risks products. It also provides property insurance products, such as property, marine, boiler, and machinery coverages; casualty insurance products comprising workers' compensation, general and product liability, commercial auto, and umbrella coverages; specialized loss-sensitive insurance programs and total risk management services; and run-off long term care policies. In addition, the company offers long-tail exposures comprising commercial automobile liability, workers compensation, general and medical professional liability, other professional and management liability, and assumed reinsurance run-off and products liability; and short-tail exposures, such as property, commercial automobile physical damage, marine, surety, and warranty. It markets its products through independent agents, brokers, and general underwriters to small, medium, and large businesses; insurance companies; associations; professionals; and other groups in the marine, oil and gas, construction, manufacturing, life science, property, financial services, healthcare, and technology industries. The company was founded in 1853 and is headquartered in Chicago, Illinois. CNA Financial Corporation operates as a subsidiary of Loews Corporation.
Earnings Per Share
As for profitability, CNA Financial Corporation has a trailing twelve months EPS of $4.73.
PE Ratio
CNA Financial Corporation has a trailing twelve months price to earnings ratio of 9.17. Meaning, the purchaser of the share is investing $9.17 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.48%.
Volume
Today’s last reported volume for CNA Financial Corporation is 403341 which is 130.02% above its average volume of 175348.
Sales Growth
CNA Financial Corporation’s sales growth is 32.4% for the present quarter and 10.6% for the next.
5. Inter Parfums (IPAR)
9.2% sales growth and 24.45% return on equity
Inter Parfums, Inc., together with its subsidiaries, manufactures, markets, and distributes a range of fragrances and fragrance related products in the United States and internationally. The company operates in two segments, European Based Operations and United States Based Operations. It offers its fragrance and cosmetic products under the Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade New York, Lanvin, Montblanc, Paul Smith, Repetto, Rochas, S.T. Dupont, Van Cleef & Arpels, Abercrombie & Fitch, Anna Sui, bebe, Dunhill, Hollister, French Connection, Graff, GUESS, Lily Aldridge, MCM, Bella Vita, and Oscar de la Renta brand names, as well as under the Intimate and Aziza names. It sells its products to department stores, specialty stores, duty free shops, beauty retailers, and domestic and international wholesalers, and distributors, as well as through e-commerce. The company was formerly known as Jean Philippe Fragrances, Inc. and changed its name to Inter Parfums, Inc. in July 1999. Inter Parfums, Inc. was founded in 1982 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Inter Parfums has a trailing twelve months EPS of $4.94.
PE Ratio
Inter Parfums has a trailing twelve months price to earnings ratio of 28.25. Meaning, the purchaser of the share is investing $28.25 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.45%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 38.5% and a negative 1.2%, respectively.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Dec 13, 2023, the estimated forward annual dividend rate is 2.5 and the estimated forward annual dividend yield is 1.79%.
6. Regeneron Pharmaceuticals (REGN)
8.3% sales growth and 17.22% return on equity
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Earnings Per Share
As for profitability, Regeneron Pharmaceuticals has a trailing twelve months EPS of $35.1.
PE Ratio
Regeneron Pharmaceuticals has a trailing twelve months price to earnings ratio of 26.8. Meaning, the purchaser of the share is investing $26.8 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.22%.
Volume
Today’s last reported volume for Regeneron Pharmaceuticals is 274058 which is 51.62% below its average volume of 566513.
Yearly Top and Bottom Value
Regeneron Pharmaceuticals’s stock is valued at $940.83 at 00:22 EST, under its 52-week high of $943.00 and way above its 52-week low of $684.81.
Previous days news about Regeneron Pharmaceuticals(REGN)
- According to Zacks on Monday, 22 January, "Some other top-ranked biotech companies are Regeneron Pharmaceuticals (REGN Quick QuoteREGN – Free Report) , Puma Biotechnology (PBYI Quick QuotePBYI – Free Report) and Fusion Pharmaceuticals (FUSN Quick QuoteFUSN – Free Report) . "
7. Antero Midstream Partners LP (AM)
7.4% sales growth and 16.23% return on equity
Antero Midstream Corporation owns and operates midstream energy assets. It owns and operates natural gas gathering pipelines, compression stations, processing and fractionation plants, and water handling and treatment assets in the Marcellus Shale and Utica Shale basins. The company was founded in 2013 and is headquartered in Denver, Colorado.
Earnings Per Share
As for profitability, Antero Midstream Partners LP has a trailing twelve months EPS of $0.73.
PE Ratio
Antero Midstream Partners LP has a trailing twelve months price to earnings ratio of 16.95. Meaning, the purchaser of the share is investing $16.95 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.23%.
Moving Average
Antero Midstream Partners LP’s worth is under its 50-day moving average of $12.68 and higher than its 200-day moving average of $11.74.
